Mechanism of Action means, with respect to a target, modulation of such target by a compound via a given mechanism of action (whether inhibition or activation).
Mechanism of Action or “MOA” means each of the DCM1 MOA, the HCM1 MOA and the HCM2 MOA.
Mechanism of Action means Orexin-1 receptor antagonism,
Examples of Mechanism of Action in a sentence
Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.
Structure and Mechanism of Action of Sda, an Inhibitor of the Histidine Kinases that Regulate Initiation of Sporulation in Bacillus subtilis.
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis.
Mechanism of Action & Proof-of-Concept▪ 4 patients treated by Dr. Wiseman in 2004-2005 (original patients), including one remarkable responder.▪ 23 patients were dosed in 2017-2018 (Phase I/IIa), all very heavily pre-treated (with chemotherapy).▪ Safety & Efficacy Data: We believe the data was similar or superior to those of other advanced or approved drugs for breast cancer at similar stages of clinical development.
Mechanism of Action: The active ingredient in this product inhibits an enzyme found only in plants and microorganisms that is essential to the formation of specific amino acids.No Soil Activity: This product binds tightly to soil particles and does not provide residual weed control.
More Definitions of Mechanism of Action
Mechanism of Action means, for Selinexor, Verdinexor, or Eltanexor, the binding to the nuclear export protein, Exportin 1, or XPO1, causing inhibition of the activity of XPO1 or otherwise reducing the nuclear export of XPO1’s cargo proteins, and for KPT-9274, it means causing dual inhibition of NAMPT and PAK4.
Mechanism of Action means, with respect to a Checkpoint Blockade Agent, [***].
Mechanism of Action means that the relevant Third Party FOB binds to the same antigen as the Product.
Mechanism of Action means the specific biological and/or chemical interaction(s) through which a drug substance produces its pharmacological effect(s).
Mechanism of Action. The epipodophyllotoxins exert phase specific spindle poison activity with metaphase arrest, but in contrast to the vinca-alkaloids, have an additional activity of inhibiting cells from entering mitosis. Suppression of tritiated thymidine, uridine, and leucine incorporation in human cells in tissue culture suggests effects against DNA, RNA, and protein synthesis.
Mechanism of Action or “MoA” means the results on the [********] criteria set forth on Schedule 1.82 (based on the corresponding measurement set forth on Schedule 1.82) at the applicable Protein Target Profile, taking each such criterion into account. A compound has “substantially the same” Mechanism of Action or MoA as another compound if (i) the two compounds have the same Protein Target Profile and the results of the first compound and the second compound on each of such measurements at [********] the NNR Subtypes included in the applicable Protein Target Profile are [********] for such measurement shown on Schedule 1.82 (provided that, where there are alternative measurements (or assays used to make such measurement) that may be
Mechanism of Action means the specific biological and/or chemical interaction(s) through which a drug substance produces its pharmacological effect(s). 1.79 “Medical Affairs” means any and all activities conducted by or on behalf of a Party or any of its Affiliates with respect to: communications with key opinion leaders, continuing medical education, symposia, advisory boards (to the extent related to medical affairs or clinical guidance), patient or consumer registries, and other medical programs and communications (including publications and exhibiting and presenting at seminars and conventions), health economic studies, health care professional programs, engaging medical science liaisons, and conducting medical science liaison activities. 1.80 “Milestone Event” has the meaning set forth in Section 13.2. 1.81 “Milestone Payment” has the meaning set forth in Section 13.2. 1.82 “Nirogacestat” has the meaning set forth in the Recitals hereto. 1.83 “Non-Conformance” has the meaning set forth to such term in the Clinical Quality Agreement. 1.84 “Non-Filing Party” has the meaning set forth in Section 17.4(b). 1.85 “Opting-out Party” has the meaning set forth in Section 17.4(b). 1.86 “Party” has the meaning set forth in the preamble. 1.87 “Personal Data” will be construed in accordance with the GDPR to the extent applicable. In all other instances, to the extent HIPAA applies, Personal Data means Protected Health Information subject to HIPAA. 1.88 “Pfizer Agreement” has the meaning set forth in Section 20.9. 1.89 “Pharmacovigilance Agreement” means that certain pharmacovigilance agreement entered into by the Parties under the Original Agreement, as may be amended pursuant to Article 10 hereof regarding safety-related activities in relation to the Compounds. 1.90 “Platform Study” means the Clinical Study entitled “Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5) (NCT04126200)” that is sponsored by GSK, under which the Sub-Study is being conducted. 1.91 “Platform Study IND” has the meaning set forth in Section 4.5. 1.92 “Platform Study Protocol” means the written documentation which describes the Platform Study and sets forth specific activities to be performed as part of the Platform Study conduct. 1.93 “Pricing and Reimbursement Approval” means any approval, agreement, determination, or other decision by the applicable Regulatory Authority or other gover...